Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Celecoxib may be effective in preventing lung cancer in tobacco smokers. PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing non-small cell lung cancer in tobacco smokers.
Checked against the public recordLast updated Aug 3, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Prevention
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Jonsson Comprehensive Cancer Center
- Interventions being studied
- Drug: celecoxib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age \> 45 * Smoked \> 20 pack years Exclusion Criteria: * Concurrent use of NSAIDs * Hypersensitivity to celecoxib * Documented allergic-type reaction to sulfonamides * History of allergic reaction, urticaria or asthma to aspirin or other NSAIDs * History of liver dysfunction * Hypertension or cardiac conditions aggravated by fluid retention and edema * Previous history of gastrointestinal ulceration, bleeding, or perforation * Renal dysfunction * End stage respiratory disease * Unstable angina * Other malignancy * Pregnancy * Concurrent use of medication known to alter or be affected by alteration of the hepatic p450 2C9 and 2D6 enzymes * Patents with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow up schedule
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Jonsson Comprehensive Cancer Center, UCLALos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 3, 2020. Always confirm current availability with the study team.